Covid-19 Updates | Biopharmaceutical Contract Manufacturing Market is estimated to be worth USD 13.9 billion in 2030
Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages

RootsAnalysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market, 2021-2030.” 

Thereport features an extensive study on the contract service providers within thebiopharmaceutical industry. The study features in-depth analysis, highlightingthe capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongstother elements, the report includes:

·       A detailed review of the overall landscape ofthe biopharmaceutical contract manufacturing market, featuring a comprehensivelist of active CMOs and detailed analysis of the manufacturing serviceproviders based on a number of parameters.

·       Elaborate profiles of key players that have adiverse range of capabilities for the development, manufacturing, and packagingof biologics.

·       A detailed discussion on the key enablers inthis domain, including certain niche product classes, which are likely to havea significant impact on the growth of the contract services market.

·       A case study on the growing globalbiosimilars market, highlighting the opportunities for biopharmaceutical CMOsand CDMOs.

·       A case study comparing the keycharacteristics of large molecule and small molecule drugs, along with detailson the various steps involved in their respective manufacturing processes.

·       A discussion on challenges related toin-house manufacturing, featuring a brief overview of the various parametersthat a drug / therapy developer may need to take into consideration whiledeciding whether to manufacture its products in-house or outsource.

·       An analysis of the recent collaborations(signed since 2013) focused on the contract manufacturing of biologics.

·       A detailed analysis of the various mergersand acquisitions that have taken place in this domain, highlighting the trendin the number of companies acquired between 2013-2018, along with thegeographical distribution of this activity.

·       An in-depth analysis of more than 490 grantsthat have been awarded to research institutes engaged in next generation immunecheckpoint therapy-related projects.

·       An analysis on the recent trends withinbiopharmaceutical contract manufacturing industry, highlighting variousfacility and capability expansions.

·       A detailed capacity analysis, taking intoconsideration the individual development and manufacturing capacities ofvarious stakeholders.

·       A detailed capacity analysis, taking intoconsideration the individual development and manufacturing capacities ofvarious stakeholders.

·       A discussion on affiliated trends, keydrivers, and challenges, under a comprehensive SWOT framework.

·       A survey analysis featuring inputs solicitedfrom various experts who are directly / indirectly involved in providing CMOservices to medical device developers.

Requestfor Customization:     

Adetailed market forecast, featuring analysis of the current and projectedfuture opportunity across key market segments (listed below)

CommonlyOutsourced Business Operations

·       Active Pharmaceutical Ingredients (API)

·       Finished Dosage Formulations (FDF)

Typesof Expression System

·       Mammalian

·       Microbial

·       Others


·       Small

·       Mid-Sized

·       Large and Very Large

Scaleof Operation

·       Preclinical

·       Clinical

·       Commercial

KeyGeographical Region

·       North America

·       Europe

·       Asia-Pacific

·       Rest of the World

Thereport also features detailed transcripts of discussions held with thefollowing experts:

·       Astrid Brammer, Senior Manager BusinessDevelopment, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)

·       Birgit Schwab, Senior Manager StrategicMarketing, Rentschler Biotechnologie

·       Christian Bailly, Director of CDMO, PierreFabre

·       Claire Otjes, Assistant Marketing Manager,Batavia Biosciences

·       David C Cunningham, Director CorporateDevelopment, Goodwin Biotechnology

·       Dietmar Katinger, Chief Executive Officer,Polymun Scientific

·       Denis Angioletti, Chief Commercial Officer,Cerbios-Pharma

·       Jeffrey Hung, Chief Commercial Officer,Vigene Biosciences

·       Kevin Daley, Director Pharmaceuticals,Novasep

·       Mark Wright, Site Head, Grangemouth, PiramalHealthcare

·       Nicolas Grandchamp, R&D Leader, GEG Tech

·       Raquel Fortunato, Chief Executive Officer,GenIbet Biopharmaceuticals

·       Sebastian Schuck, Head of BusinessDevelopment, Wacker Biotech

·       Stephen Taylor, Senior Vice PresidentCommercial, FUJIFILM Diosynth Biotechnologies

·       Tatjana Buchholz, Marketing Manager,PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory

·       Tim Oldham, Chief Executive Officer, CellTherapies

Keycompanies covered in the report

·       3P Biopharmaceuticals

·       Abzena

·       Albany Molecular Research

·       BioVectra

·       BioXcellence (Boehringer Ingelheim)

·       Celonic

·       Charles River Laboratories

·       ChemPartner

·       Cobra Biologics

·       CordenPharma

·       Cytovance Biologics

·       GE Healthcare

·       Goodwin Biotechnology

·       Grand River Aseptic Manufacturing

·       IDT Biologika

·       KBI BioPharma

·       Kemwell Biopharma

·       LFB Biomanufacturing

·       Meridian Life Science

·       Patheon

·       Pfizer CentreOne

·       PX'Therapeutics

·       Samsung BioLogics

·       Sanofi, CEPiA

·       Thermo Fisher Scientific

·       Vetter Pharma International

Formore information, please click on the following link:    

AlsoVisit Our Latest Publication:

Cloud-based Solutions for Drug Discovery,Development and Manufacturing Market

CAR-T Cell Therapies Market

Patient Recruitment and Retention ServicesMarket

mRNA Therapeutics and Vaccines Market

T-Cell (CAR-T, TCR, and TIL) TherapiesMarket

AboutRoots Analysis

RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at [email protected]


RootsAnalysis Private Limited


+1(415) 800 3415

[email protected]


You may also like

Facebook Conversations

Disqus Conversations